Browsing by Author "Arabul, Mahmut"

Now showing 1 - 12 of 12

Anxiety, depression and peritoneal dialysis
(Oxford University Press, 2006) Kahvecioğlu, Serdar; Akdağ, İbrahim; Yavuz, Mahmut; Arabul, Mahmut; Dilek, Kamil; Ersoy, Alpaslan; Güllülü, Mustafa; Yurtkuran, Mustafa; Uludağ Üniversitesi/Tıp Fakültesi.; 0000-0002-0710-0923; AAH-5054-2021
Comparison of higher dose of losartan treatment with losartan plus carvedilol and losartan plus ramipril in patients with glomerulonephritis and proteinuria
(Taylor & Francis Ltd, 2007) Kahvecioğlu, Serdar; Akdaǧ, İbrahim; Güllülü, Mustafa; Arabul, Mahmut; Ersoy, Alparslan; Dilek, Kamil; Yavuz, Mahmut; Yurtkuran, Mustafa Abbas; Uludağ Üniversitesi/Tıp Fakültesi/Nefroloji Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Anabilim Dalı.; 0000-0002-0710-0923; AAH-5054-2021; 55956719500; 8342488100; 6602684544; 15925230900; 35612977100; 56005080200; 7006244754; 7003389525
Background. Proteinuria may cause a worsening of accompanying renal disease or even lead to glomerulosclerosis. There is no data about the effect of carvedilol on patients with proteinuric (> 0.5 g/day) glomerulonephritis. This study aimed to compare the effects of carvedilol with ramipril and losartan in patients with proteinuric glomerulonephritis. Methods. Twenty-one glomerulonephritis patients were followed for 12 months. Patients were divided into three groups. All patients were treated with losartan 50 mg once daily for two weeks. After two weeks (baseline), patients were given additional medications: 50 mg losartan, 5 mg ramipril, and 25 mg carvedilol were given additionally to the patients in groups 1, 2, and 3 respectively. Results. Baseline mean proteinuria values of patients in groups 1, 2 and 3 were 1.6 +/- 1.1 g/day, 2.1 +/- 1.3 g/day, and 1.4 +/- 1.2 g/day, respectively. These values decreased to 0.5 +/- 0.7 g/day, 0.6 +/- 0.7 g/day, and 0.9 +/- 0.9 g/day, respectively, at the end of the 12(th) month. These results were statistically significant only in group 1 (p = 0.04). The rational variation of proteinuria between the first and 12(th) month of losartan, ramipril, and carvedilol were -61%, -62%, and -27%, respectively. The decreases in blood pressures between baseline and the first, sixth, and twelfth-month measurements were significant in all groups. Conclusions. Thee results showed that angiotensin-converting enzyme inhibitors (ACEls) and angiotensin receptor blockers (AT1ras) provide marked decreases in proteinuria, making their use indisputable in patients with glomerulonephritis. Carvedilol was not found to be as effective as ACEIs and AT1ras in decreasing proteinuria and preserving renal function.
Decreased plasma levels of soluble receptor for advanced glycation endproducts (sRAGE) in patients with nonalcoholic fatty liver disease
(Pergamon-Elsevier Science, 2009-06) Atuğ, Özlen; Yılmaz, Yusuf; Ulukaya, Engin; Gül, Özen Öz; Arabul, Mahmut; Gül, Cuma Bülent; Oral, Arzu Yılmaztepe; Aker, Sibel; Dolar, Mahmut Enver; Uludağ Üniversitesi/Tıp Fakültesi/Biyokimya Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/Endokrinoloji Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/Dahiliye Anabilim Dalı.; 0000-0003-2467-9356; 0000-0003-0463-6818; 0000-0003-4518-5283; A-7063-2018; AAI-1005-2021; AAG-9177-2021; A-5841-2017; K-5792-2018; 22936014300; 6602927353; 26040787100; 15925230900; 23988796000; 23091316500; 12795285000; 6602075084
Objectives: Levels of soluble receptor for advanced glycation endproducts (sRAGE) have been linked to several components of the metabolic syndrome. We tested the hypothesis that plasma levels of sRAGE may be associated with non-alcoholic fatty liver disease. Design and methods: We enrolled subjects with definite nonalcoholic steatohepatitis (NASH, n=40), borderline NASH (n=8), simple fatty liver (n=9) and healthy controls (n=14). Plasma levels of sRAGE were measured by ELISA. Results: Concentrations of sRAGE were significantly lower in patients with definite NASH (1080 +/- 392 pg/mL, P<0.01) and borderline NASH (1050 +/- 278 pg/mL, P<0.05) compared to controls (1480 +/- 387 pg/mL). Levels of sRAGE were significantly and inversely correlated with ALT (r=-0.30, P<0.05) and AST (r=-0.23, P<0.05). Conclusion: Plasma levels of sRAGE are significantly reduced in definite and borderline NASH.
Diyaliz hastalarında statin tedavisinin renal anemi-inflamasyon ve prohepcidin üzerine etkileri
(Uludağ Üniversitesi, 2008) Arabul, Mahmut; Güllülü, Mustafa; Uludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Anabilim Dalı/Nefroloji Bilim Dalı.
Kronik hastalık anemisi kronik infeksiyonlarda, kanserlerde, travmada veinflamatuar hastalıklarda sıklıkla gözlenir. Son zamanlara kadar patogenezihakkında çok az sey biliniyordu. Son bir kaç yıldır, kronik hastalık anemisipatogenezinde bir inflamatuar sitokin olan IL-6'nın uyardıgı hepcidin ön planaçıkmıstır. Hepcidin demir düzenleyicisi olmakla birlikte kronik hastalıkanemisinden de sorumlu tutulmaktadır.Hepcidin bir antimikrobiyal peptid olup esas olarak karacigerdesentezlenir. Hepcidinin dietten demir emilimini ve makrofajlardan vekaracigerdeki demir depolarından demirin mobilizasyonunu düzenledigi önesürülmektedir. İnflamasyon kronik hastalık anemisinin güçlü mediatörü olanhepcidinin üretimini artırır.Kronik böbrek yetmezliginde (KBY) anemi esas olarak eritropoetin (EPO)eksikliği yüzündendir. Fakat bu hastalarda sıklıkla kronik inflamatuar bir durumsözkonusudur. Kronik inflamasyonun altında üremik ortam, artmısproinflamatuar sitokinler, infeksiyonlar, aterosklerozis vs. gibi birçok nedenbulunmaktadır. Diyaliz hastalarında artmıs hepcidin seviyeleri fonksiyonel demireksikliginden ve anemiden sorumlu olabilir. Diyaliz hastalarında sıklıkla düsükdüzeyde bir inflamasyon ve aynı zamanda düzeyi artmıs hepcidin mevcuttur.Son zamanlarda öne sürülen hipoteze göre; KBY'de hepcidin ile anemi,inflamasyon ve karaciger fonksiyonları arasında bir iliski olabilir.Biz çalısmamızda diyaliz hastalarında anemi, inflamasyon parametreleriile hepcidin iliskisini göstermeyi ve statinlerin anemi, inflamasyon ve hepcidinparametrelerine etkisini arastırmayı amaçladık. Statinlerin anti-inflamatuaretkisinden yararlanarak kronik inflamasyon-anemi döngüsünü kırıp anemiyekatkıda bulunmayı hedefledik. Biz çalısmaya 40 hasta (hemodiyaliz: 21, peritondiyaliz: 19) aldık. Hastaları hs-CRP<6 (Grup A: 26, hemodiyaliz: 14, peritondiyaliz: 12) ve hs-CRP>6 (Grup B: 14, hemodiyaliz: 7, periton diyaliz: 7)degerlerine göre grupladık. Hastaların 22 tanesi tedavi grubu, 18 tanesi kontrolgrubu idi. Prohepcidinin EPO dozlarından, demir parametrelerinden, kronikinflamasyondan ne ölçüde etkilendigini ortaya koymaya çalıstık.ilk kez, düsük seviyede inflamasyona sahip diyalize giren hasta grubundastatin tedavisinin inflamasyon ve anemi belirteci olan prohepcidini anlamlıbiçimde azalttıgını (p < 0.05) gösterdik.
Diyaliz ve erektil disfonksiyon
(Uludağ Üniversitesi, 2004-12-20) Kahvecioğlu, Serdar; Akdağ, İbrahim; Arabul, Mahmut; Görgülü, Numan; Ersoy, Alpaslan; Güllülü, Mustafa; Yavuz, Mahmut; Dilek, Kamil; Yurtkuran, Mustafa; Uludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Anabilim Dalı/Nefroloji Bilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Anabilim Dalı.
Kişiler tarafından dile getirilmekten çekinilen ve kronik hastalıklar ile psikiyatrik bozukluğu olanlarda sıklığı artan erektil disfonksiyon (ED) sağlıklı erişkin erkeklerde yaklaşık %50 oranındadır. Çalışmamızda, erkeklerde bu kadar sık görülen bu hastalığın ünitemizdeki renal replasman tedavisi alan hemodiyaliz (HD) ve periton diyalizi (PD) uygulanan olgularımızdaki sıklığını ve psikiyatrik tablo ile ED bağlantısını araştırmayı amaçladık. Bu amaçla çalışmaya 18 HD, 9 PD hastası ve 14 gönüllü sağlıklı kontrol grubu olarak alındı. Tüm olgulardan ED uluslar arası indeks formu, hastane anksiyete ve depresyon formunun cevaplanması istendi. HD’de %50, PD’de %66 ve kontrol grubunda %35 oranında ED’a rastlandı. HD grubunda psikiyatrik bozukluğu olan hastalarda ED sıklığının arttığı diğer gruplarda istatistiksel anlamlılığa ulaşmadığı görüldü.
Effect of fluvastatin on serum prohepcidin levels in patients with end-stage renal disease
(Pergamon-Elsevier Science, 2008-09) Arabul, Mahmut; Güllülü, Mustafa; Yılmaz, Yusuf; Akdağ, İbrahim; Kahvecioğlu, Serdar; Eren, Mehmet Ali; Dilek, Kamil; Uludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/Nefroloji ve Romatoloji Anabilim Dalı.; 0000-0003-4518-5283; ABH-7279-2020; 15925230900; 6602684544; 22936014300; 8342488100; 55956719500; 7006788432; 56005080200
Objectives: Anemia, low-grade inflammation and/or alterations in lipid metabolism are common findings in individuals with end-stage renal disease (ESRD) despite advances in dialysis treatment. Hepcidin, a key regulator of iron metabolism, may play an important role in the interdependence of inflammation and anemia in ESRD patients. Statins may reduce cardiovascular events in dialysis patients and have pleiotropic effects in addition to lowering total and low-density lipoprotein (LDL)-cholesterol. Design and methods: Because there is a paucity of data on the effect of statins on serum prohepcidin levels in dialysis patients, this 8-week study was conducted to test the effect of fluvastatin (80 mg/day, n = 22) compared with placebo (n = 18) on circulating scruin prohepcidin, a prohormone of hepcidin, and high-sensitive C-reactive protein (hs-CRP) in dyslipidemic ESRD patients with renal anemia. Results: Fluvastatin treatment decreased total cholesterol (P < 0.05), LDL-cholesterol (P < 0.01), hs-CRP (P < 0.05) and serum prohepcidin levels (P < 0.05) significantly. Conclusion: Our pilot data suggest that short-term statin treatment may exert a beneficial effect on serum prohepcidin levels in ESRD patients. The potential clinical benefits of statins on renal anemia need to be confirmed and expanded with an appropriately powered long-term study.
Erectile dysfunction and sexual problems in peritoneal dialysis patients
(Oxford University Press, 2006) Kahvecioğlu, Serdar; Akdağ, İbrahim; Yavuz, Mahmut; Arabul, Mahmut; Dilek, Kamil; Ersoy, Alpaslan; Güllülü, Mustafa; Uludağ Üniversitesi/Tıp Fakültesi.; 0000-0002-0710-0923; AAH-5054-2021
Helicobacter pylori: A role in schizophrenia?
(INT Scientific Information, 2008-07) Yılmaz, Yusuf; Gül, Cuma Bülent; Arabul, Mahmut; Eren, Mehmet Ali; Uludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Anabilim Dalı.; 0000-0003-2467-9356; 0000-0003-4518-5283; A-7063-2018; K-6651-2012; ABH-7279-2020; 22936014300; 23988796000; 15925230900; 7006788432
Schizophrenia is a devestating psychiatric disorder that affects approximately one percent of the world's adult population. Despite substantial investigative efforts over the last decades, the exact mechanisms and pathogenesis of this condition are not yet fully understood. Published data support certain infectious agents as potential risk factors for schizophrenia. Since its discovery, Helicobacter pylori has been implicated in a variety of extradigestive diseases, but its potential role in the pathogenesis of psychiatric disorders has thus far been neglected. It is hypothesized here that infection with H. pylori occurring in early childhood may induce persisting systemic biochemical aberrations, including dopaminergic dysfunction, decreased levels of essential polyunsaturated fatty acids, subtle inflammation, and homocysteine alterations, that may play a crucial role in the development of schizophrenia in genetically predisposed individuals. Evidence in favor of this hypothesis is provided and possible therapeutic implications are discussed.
Hypothyroidism is not associated with specific histological features or severity of non-alcoholic fatty liver disease
(Elsevier, 2013-04) Yılmaz, Yusuf; Çolak, Yaşar; Senates, Ebubekir; Arabul, Mahmut; Ünsal, Belkıs; Tuncer, İlyas; Ayyıldız, Talat; Dolar, Mahmut Enver; Uludağ Üniversitesi/Tıp Fakültesi/Gastroenteroloji Anabilim Dalı.; 0000-0001-8944-2793; AAG-9177-2021
Influence of erythropoietin therapy on serum prohepcidin levels in dialysis patients
(INT Scientific Information, 2009-11) Arabul, Mahmut; Güllülü, Mustafa; Yılmaz, Yusuf; Eren, Mehmet Ali; Baran, Bülent; Gül, Cuma Bülent; Kocamaz, Güzin; Dilek, Kamil; Uludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/Nefroloji ve Romatoloji Anabilim Dalı.; 0000-0003-2467-9356; 0000-0003-4518-5283; 0000-0001-7966-2346; A-7063-2018; ABH-7279-2020; K-6651-2012; A-7978-2012; 15925230900; 6602684544; 22936014300; 7006788432; 35955740500; 23988796000; 23995302100; 56005080200
Background: Anemia is a common finding in dialysis patients. Recent evidence has accrued that hepcidin, an iron regulatory peptide, may play a crucial role in the pathophysiology of this condition. This study investigated the effect of erythropoietin (EPO) therapy on serum levels of prohepcidin, the prohormone of hepcidin, in patients with end-stage renal disease (ESRD) undergoing chronic dialysis treatment. Material/Methods: A total of 40 ESRD patients with renal anemia receiving either hemodialysis or peritoneal dialysis were included in this study. The patients were randomly allocated to EPO (subcutaneous 2000 mu g three times weekly) plus parenteral iron (n=23) or parental iron only (n=17). Serum prohepcidin levels were measured before and at the end of the study. Results: The two groups were comparable in their demographic and laboratory characteristics. No significant differences were found in hemoglobin, hematocrit, iron store indices, or serum levels of prohepcidin at study entry. Significant increases in both hemoglobin and hematocrit as well as a decrease in serum prohepcidin level were evident in the EPO group at the end of the 6-month follow-up in comparison with their values at study entry compared with the control group (P < 0.01). Conclusions: It is concluded that EPO therapy, besides enhancing erythropoiesis, modulates serum prohepcidin levels in dialysis patients.
Plasma levels of soluble receptor for advanced glycation endproducts (srage) in patients with nonalcoholic fatty liver disease
(Elsevier, 2009) Yılmaz, Yusuf; Atuğ, Özlen; Ulukaya, Engin; Gül, Özen Öz; Arabul, Mahmut; Gül, Cuma Bülent; Oral, Arzu Yılmaztepe; Dolar, Mahmut Enver; Uludağ Üniversitesi/Tıp Fakültesi/Biyokimya Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/Endokrinoloji ve Metabolizma Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/Dahili Tıp Bilimleri Bölümü.; Uludağ Üniversitesi/Tıp Fakültesi/Gastroenteroloji Anabilim Dalı.; 0000-0003-2467-9356; 0000-0003-0463-6818; AAG-9177-2021; A-7063-2018; A-5841-2017; AAI-1005-2021; K-5792-2018
Relationship between prohepcidin and cardiovascular risk markers in end stage renal failure patients
(Türk Nefroloji Diyaliz Transplantasyon Dergisi, 2013-01-01) Arabul, Mahmut; Kahvecioğlu, Serdar; Eren, Mehmet Ali; Üstündağ, Yasemin; Sarandöl, Emre; Kaderli, Aysel; Emre, Türker; Doğan, İbrahim; Güllülü, Mustafa; Kaderli, Aysel; SARANDÖL, EMRE; GÜLLÜLÜ, MUSTAFA; Uludağ Üniversitesi/Tıp Fakültesi/Kardiyoloji Anabilim Dalı; Uludağ Üniversitesi/Tıp Fakültesi/Nefroloji Anabilim Dalı; IDI-7594-2023; JGS-9425-2023; ABE-1716-2020
OBJECTIVE: The leading cause of death in patients with end-stage renal disease (ESRD) is cardiovascular disease. Prohepcidin, which is the precursor of hepcidin is a peptide hormone produced by the liver, and appears to be the master regulator of iron homeostasis in humans. High prohepcidin levels may contribute to progression of cardiovascular disease in end-stage renal insufficiency patients. However, any such association remains poorly understood. The purpose of the present study was to investigate the relationship between prohepcidin and cardiovascular risk markers in end-stage renal failure patients.MATERIAL and METHODS: Twenty-two chronic hemodialysis patients, 21 chronic peritoneal dialysis patients, and 16 healthy controls were included in the present study. The levels of serum prohepcidin (the precursor form of hepcidin), high sensitivity C-reactive protein (hs-CRP), troponin-T (TT), and cystatin C (CC) were determined using commercial kits. The left ventricular mass index (LVMI) was estimated using echocardiography.RESULTS: The levels of the CVD risk markers TT, CC, and prohepcidin differed, with statistical significance, between the patient and control groups. Prohepcidin level was significantly associated with CC concentration (beta=0.855, R2=0.73, p<0.001), TT level (beta=0.456, R2=0.20, p=0.002), and the LVMI (beta=0.435, R2=0.19, p=0.003). However, no significant association between prohepcidin level and hs-CRP concentration was evident (beta=0.124, R2=0.015, p<0.42).CONCLUSION: Our data suggest that the prohepcidin level can serve as a biomarker of cardiovascular disease. This level is closely associated with the cardiovascular risk markers of CC and TT concentrations, as well as the LVMI.